-
DEPOMED, INC. v. ACTAVIS ELIZABETH LLC et al DC CAFC
- 3:12-cv-01358
- D.N.J.
- Filed: 03/02/2012
- Closed: 08/19/2014
- Latest Docket Entry: 07/20/2015
- Judge: Mary Little Cooper
+1
- PACER
1
Plaintiff
7
Defendants
2
Accused
Products
8
Patents-in-Suit
901
Days in
Litigation
-
DEPOMED, INC. v. ACTAVIS ELIZABETH LLC et al DC CAFC
- 3:12-cv-01358
- D.N.J.
- Filed: 03/02/2012
- Closed: 08/19/2014
- Latest Docket Entry: 07/20/2015
- Judge: Mary Little Cooper
+1
- PACER
Cause of Action
Infringement
Market Sector
Biotech and Pharma
Court
Referred Judge
Assigned Judge
Outcome Summary
Patent Information
-
Infringement
Actavis Elizabeth LLC
- 7 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 300 mg gabapentin extended-release tablets600 mg dosage strength600 mg gabapentin extended-release tabletsGabapentin extended-release tablets in the 300 | US 6,488,962 B1 |
5, 8, 10, 13
|
Infringement
Entry 376Entry 383 |
| 300 mg gabapentin extended-release tablets600 mg dosage strength600 mg gabapentin extended-release tabletsGabapentin extended-release tablets in the 300 | US 6,635,280 B2 |
1, 12, 14, 45
|
Infringement
Entry 376Entry 383 |
| 300 mg gabapentin extended-release tablets600 mg dosage strength600 mg gabapentin extended-release tabletsGabapentin extended-release tablets in the 300 | US 7,438,927 B2 |
18, 25, 26, 34, 61, 62
|
Infringement
Entry 376Entry 383 |
| 300 mg gabapentin extended-release tablets600 mg dosage strength600 mg gabapentin extended-release tabletsGabapentin extended-release tablets in the 300 | US 7,731,989 B2 |
10
|
Infringement
Entry 376Entry 383 |
| 300 mg gabapentin extended-release tablets600 mg dosage strength600 mg gabapentin extended-release tabletsGabapentin extended-release tablets in the 300 | US 8,192,756 B2 |
1, 2, 5, 6, 7, 11
|
Infringement
Entry 376Entry 383 |
| 300 mg gabapentin extended-release tablets600 mg dosage strength600 mg gabapentin extended-release tabletsGabapentin extended-release tablets in the 300 | US 8,252,332 B2 |
1, 6, 17, 22, 24
|
Infringement
Entry 376Entry 383 |
| 300 mg gabapentin extended-release tablets600 mg dosage strength600 mg gabapentin extended-release tabletsGabapentin extended-release tablets in the 300 | US 8,333,992 B2 |
1, 5, 22
|
Infringement
Entry 376Entry 383 |
Actavis Incorporated
- 7 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 300 mg gabapentin extended-release tablets600 mg dosage strength600 mg gabapentin extended-release tabletsGabapentin extended-release tablets in the 300 | US 6,488,962 B1 |
5, 8, 10, 13
|
Infringement
Entry 376Entry 383 |
| 300 mg gabapentin extended-release tablets600 mg dosage strength600 mg gabapentin extended-release tabletsGabapentin extended-release tablets in the 300 | US 6,635,280 B2 |
1, 12, 14, 45
|
Infringement
Entry 376Entry 383 |
| 300 mg gabapentin extended-release tablets600 mg dosage strength600 mg gabapentin extended-release tabletsGabapentin extended-release tablets in the 300 | US 7,438,927 B2 |
18, 25, 26, 34, 61, 62
|
Infringement
Entry 376Entry 383 |
| 300 mg gabapentin extended-release tablets600 mg dosage strength600 mg gabapentin extended-release tabletsGabapentin extended-release tablets in the 300 | US 7,731,989 B2 |
10
|
Infringement
Entry 376Entry 383 |
| 300 mg gabapentin extended-release tablets600 mg dosage strength600 mg gabapentin extended-release tabletsGabapentin extended-release tablets in the 300 | US 8,192,756 B2 |
1, 2, 5, 6, 7, 11
|
Infringement
Entry 376Entry 383 |
| 300 mg gabapentin extended-release tablets600 mg dosage strength600 mg gabapentin extended-release tabletsGabapentin extended-release tablets in the 300 | US 8,252,332 B2 |
1, 6, 17, 22, 24
|
Infringement
Entry 376Entry 383 |
| 300 mg gabapentin extended-release tablets600 mg dosage strength600 mg gabapentin extended-release tabletsGabapentin extended-release tablets in the 300 | US 8,333,992 B2 |
1, 5, 22
|
Infringement
Entry 376Entry 383 |